Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries
Kaoru Yamabe,1 Marco D DiBonaventura,2 Chris L Pashos3 1Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Chuouku, Tokyo 103-8668, Japan; 2Health Outcomes, Kantar Health, New York, NY 10010, USA; 3Global Outcomes and Epidemiology Research. Data Sciences Institute, Takeda Pharmaceu...
Saved in:
Main Authors: | Yamabe K (Author), DiBonaventura MD (Author), Pashos CL (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Health-related quality of life outcomes, economic burden, and associated costs among diagnosed and undiagnosed depression patients in Japan
by: Yamabe K, et al.
Published: (2019) -
Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan
by: Yamabe K, et al.
Published: (2019) -
Health-related outcomes and economic burden in Japan: focus on inflammatory bowel disease, multiple sclerosis, and depression
by: Yamabe K
Published: (2018) -
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
by: Bonafede MM, et al.
Published: (2013) -
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
by: Burks J, et al.
Published: (2017)